Johnson & Johnson Facing Risperdal Lawsuit
Risperdal is one of a numerous amount of anti-psychotic drugs used to treat depression and other mental health conditions, such as bi-polar disease. A new lawsuit is alleging , and potentially proving, that Johnson & Johnson hid three studies linking the drug to diabetes. As early as 1999, Johnson & Johnson’s Janssen unit had researchers’ findings that about half the patients taking Risperdal in ...
J&J Hid 3 Risperdal Diabetes Studies From FDA, Texas Jury Told
Johnson & Johnson (JNJ) officials hid three studies showing some patients using Risperdal developed diabetes while claiming the antipsychotic drug didn’t cause the disease, a witness testified.
Texas suit against J&J over drug to go to trial
AUSTIN, Texas (AP) — Texas is seeking more than $1 billion in damages in a lawsuit that accuses Johnson & Johnson of overstating the safety of an anti-psychotic drug and influencing its use in the state's Medicaid program.
J&J to Pay $158 Million to Settle Texas Risperdal Drug Case
Johnson & Johnson agreed to pay $158 million to settle Texas officials’ claims that the drugmaker fraudulently marketed its Risperdal anti-psychotic drug, ending a trial over the allegations.
J&J to Pay $158M to Settle Texas Drug Case
Johnson & Johnson (JNJ) agreed to pay $158 million to settle Texas officials’ claims that the drugmaker fraudulently marketed its Risperdal anti-psychotic drug, ending a trial over the allegations.
Texas suit against J&J over drug goes to trial
A clash between Texas and Johnson & Johnson that could end up costing the drug maker $1 billion opened Tuesday with prosecutors accusing the company of plundering the state Medicaid program by overstating the safety of an expensive anti-psychotic drug and improperly influencing officials and doctors to push the medication.
Insider Trading, Goldman, Carlyle, Ally, TD in Court News
Seven men, including fund managers and analysts, were charged by the U.S. with forming a “criminal club” of friends and co-workers who reaped almost $62 million from insider trading in Dell Inc. (DELL) shares.
Johnson & Johnson has Agreed to Pay $158M in Texas Off-Label Marketing Case
Pharmaceutical giant Johnson & Johnson has agreed to a settlement that will have the New Jersery based drug manufacturer paying out $158 million to the state of Texas. Texas officials claim that J&J defrauded the state’s Medicaid program by promoting the drug Risperdal for uses not approved by the FDA, including the treatment of psychiatric disorders in children. The state also alleges that J&J ...
SC judge upholds $327M verdict for J&J marketing
TRENTON, N.J.—A South Carolina judge has upheld a $327 million civil penalty against health giant Johnson & Johnson, which in March was found guilty by a jury of overstating the safety and effectiveness of its former blockbuster antipsychotic drug, Risperdal.